





Overview

This Symposium highlights new advances in the field of translational research as it relates to pathology and features a series of insightful research presentations along with a poster session presented by members of the MSK Pathology and Laboratory Medicine Department. Additionally, the Gerald Award Lecture is an integral highlight of this annual event.

The Memorial Sloan Kettering Cancer Center (MSK) William L. Gerald Award is conferred on a pathologist whose recent innovative research has provided novel insights into cancer biology and whose career trajectory suggests the potential for outstanding contributions in the years to come.

The award reflects the contributions and values brought to the Department of Pathology by William L. Gerald, an Attending Pathologist at MSK from 1992 to 2008. A gifted morphologist, Dr. Gerald was committed to providing state-of-the-art patient care as a surgical pathologist and recognized that the molecular characterization of human neoplasms could affect the classification, prognostic assessment, and treatment of cancer. Dr. Gerald had broad diagnostic expertise but focused his clinical work on genitourinary pathology, and he was also the pediatric pathology consultant for the department. He was a pioneer in the molecular characterization of cancer at a time when now commonplace molecular techniques were still cutting-edge technology.

Dr. Gerald provided the first histologic description and subsequent molecular characterization of desmoplastic small round cell tumor, an entity that now bears his name. His work helped establish a novel molecular classification of neuroblastoma. He used gene expression analysis and other molecular assays to develop the prognostic characterization of prostate cancer.

Throughout his career, Dr. Gerald collaborated with and provided mentorship to numerous trainees and colleagues. His quiet good nature and thoughtful approach made him a model physician-scientist. He was approachable and always willing to provide key insights. This award is a tribute to his scientific contributions and personal attributes, and to the legacy he left behind.

WHO SHOULD ATTEND

This Symposium is directed toward practicing pathologists and research scientists, both in academic and private practice environments, as well as residents and fellows in pathology, who wish to broaden their understanding of neoplastic diseases.

LEARNING OBJECTIVES

At the conclusion of this program, learners will be able to:

- Provide an overview of the latest developments in translational research in pathology
- Create awareness of current methodological approaches to understand disease
- · Apply updated approaches to diagnosis of disease

complimentary registration: msk.org/strp2024



IN-PERSON OR VIRTUAL

We extend a warm invitation to attendees to join us in person at Memorial Sloan Kettering for this course located at:

Zuckerman Research Center 417 East 68th Street New York, NY

If you'll be traveling to New York City from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, Memorial Sloan Kettering has negotiated special rates and amenities at select hotels in Manhattan. Explore further details at:

msk.org/strp2024

For those unable to attend onsite, a convenient virtual option is available.

complimentary registration: msk.org/strp2024

MSK COURSE DIRECTORS



Hikmat A. Al-Ahmadie, MDAttending, Genitourinary Pathology



Lora Hedrick Ellenson, MDDirector, Gynecologic Pathology



Meera R. Hameed, MD Chief, Surgical Pathology Service



Natasha Rekhtman, MD, PhD Attending Pathologist

MSK LEADERSHIP WELCOME



Kojo S.J. Elenitoba-Johnson, MD Chair, Department of Pathology and Laboratory Medicine James Ewing Alumni Chair of Pathology

WILLIAM L. GERALD AWARDEE & LECTURER



Jorge S. Reis-Filho, MD, PhD, FRCPath Vice President, Cancer Biomarker Development AstraZeneca Gaithersburg, MD

MSK Department of Pathology and Laboratory Medicine

FACULTY

Tejus A. Bale, MD, PhD Gregory Goldgof, MD, PhD, MS Marc Ladanyi, MD Melissa P. Pulitzer, MD

FELLOWS

Susan Armstrong, MD, PhD Elisabet Pujadas, MD, PhD Theodore Vougiouklakis, MD

Schedule

FRIDAY, APRIL 19, 2024 • 1:00-7:00 PM

Zuckerman Research Center (ZRC) Auditorium

12:45 PM Registration and Check-in

ZRC Lobby

1:00 PM



INTRODUCTION & WELCOME

Kojo S. J. Elenitoba-Johnson, MD Chair, Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center

Accredited Session

This session has been accredited for AMA PRA Category 1 CreditsTM and qualifies for 1.50 Lifelong Learning (CME) credit.

1:05 PM Allele-Specific Loss or Mutations in CDKN2A/B Worsen

Overall Survival in IDH-Mutant Astrocytomas

Tejus A. Bale, MD, PhD

1:20 PM TYK2 Rearranged Primary Cutaneous T-cell Lymphoma

with Novel Presentations
Melissa P. Pulitzer. MD

1:35 PM Mutational Signature Analysis by SigMA Across

Major Cancer Subtypes Reveals Previously

Undescribed Associations Theodore Vougiouklakis, MD

1:50 PM Comparative Genomic Analysis of High-Grade Serous

Carcinoma of Adnexal/Peritoneal Origin and Uterine Serous Carcinoma: Unveiling Molecular Distinctions

and Diagnostic Implications Elisabet Pujadas, MD, PhD

2:05 PM Lung Neuroendocrine Neoplasms Harboring RET, ALK

and Other Fusions: Pathologic Features Range From Conventional Neuroendocrine Carcinomas to Unusual Low-Proliferative Neoplasms Resembling Carcinoids With Mucin — A Conundrum for Pathologic Classification

Susan Armstrong, MD, PhD

2:20 PM Deep Learning for Morphology-Based, Bone Marrow

Cell Classification

Gregory Goldgof, MD, PhD, MS

2:35 PM BREAK & POSTER SESSION

ZRC Lobby

Non-Accredited Session

Please note that Continuing Medical Education (CME) credits through *AMA PRA Category 1 Credits™* and *ABPath CC* will <u>not be available</u> for this session.

William L. Gerald Award & Lecture

4:00 PM **Award Introduction**

Marc Ladanyi, MD

4:05 PM **Award Presentation**

Kojo S. J. Elenitoba-Johnson, MD

AstraZeneca

4:10 PM



How I've Learned to Stop Worrying and Love Molecular Pathology: Advancing Biomarker Development Jorge S. Reis-Filho, MD, PhD, FRCPath Vice President, Cancer Biomarker Development

5:00 PM **NETWORKING RECEPTION**

ZRC Lobby

Course attendees and faculty are invited to a networking reception scheduled from 5:00 to 7:00 PM in the lobby.

Hors d'oeuvre and refreshments will be served.

7:00 PM Adjournment

complimentary registration: msk.org/strp2024

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **1.50** *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPATH CC RECOGNITION STATEMENT

This activity will offer **1.50 Lifelong Learning (CME) credit** towards the American Board of Pathology's Continuing Certification program.

MITIGATION OF RELEVANT FINANCIAL RELATIONSHIPS

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.







